Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1977 Mar;59(3):549-57.
doi: 10.1172/JCI108670.

Leukocyte procoagulant activity: enhancement of production in vitro by IgG and antigen-antibody complexes

Leukocyte procoagulant activity: enhancement of production in vitro by IgG and antigen-antibody complexes

H Rothberger et al. J Clin Invest. 1977 Mar.

Abstract

In a variety of immunologic diseases, fibrin-fibrinogen and immune complexes deposit in areas of tissue damage. However, the mechanisms which initiate fibrin-fibrinogen deposition have not been clarified. We find that the procoagulant activity of human leukocytes is markedly increased after incubation with immunoglobulin and immune complexes. This procoagulant activity is evident after 4-24 h incubation in the presence of as little as 0.1 mg/ml of autologous, isologous, or heterologous IgG. At least three of the four subclasses of IgG myeloma proteins are effective. Experiments with purified rabbit and rat antibodies demonstrate that enhancement of procoagulant activity is significantly greater with soluble antigen-antibody complexes than with immunoglobulin alone. In contrast, insoluble complexes are less affective than immunoglobulin alone. Artifacts due to endotoxin contamination of the IgG preparations were excluded on the basis of the differential sensitivities of immunoglobulin and endotoxin to heat and polymyxin B. Evidence is also presented which shows that enhancement of procoagulant activity involves the production, rather than a simple release, of leukocyte procoagulant activity in vitro.

PubMed Disclaimer

References

    1. Arch Dermatol. 1976 Feb;112(2):219-26 - PubMed
    1. J Exp Med. 1976 Sep 1;144(3):840-6 - PubMed
    1. J Clin Invest. 1976 Jul;58(1):142-51 - PubMed
    1. J Immunol. 1971 Jun;106(6):1647-53 - PubMed
    1. Adv Immunol. 1973;17:93-193 - PubMed

Publication types